---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-009976"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2022-06-13T23:59:59+00:00"
generated_at: "2026-06-25T02:20:56.174322+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biostage issues $4M Series E Convertible Preferred to Harvard Bioscience to satisfy indemnification

## Summary
- Issued 4,000 shares of Series E Preferred at $1,000/share to HBIO on June 10, 2022, to settle $4M indemnification obligations.
- 8% annual dividend payable quarterly in additional Series E shares; ranks senior to common stock.
- Mandatory conversion upon NASDAQ uplisting, IPO, or $4M+ private placement; optional conversion based on 60-day VWAP.
- Consent rights restrict debt over $500K, certain related-party transactions, and issuance of senior or pari passu securities.
- Beneficial ownership limitation capped at 9.99% on conversion; limited piggyback registration rights if Rule 144 unavailable.

## SEC filing metadata
- accession: 0001558370-22-009976
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2022-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000155837022009976/0001558370-22-009976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000155837022009976/tmb-20220610x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-009976
- JSON: https://secwatch.observer/filing/0001558370-22-009976.json
- Plain text: https://secwatch.observer/filing/0001558370-22-009976.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.